Serina Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company listed on the NYSE American market (NYSE/NASDAQ ecosystem, United States) under the ticker SER. For French-, Belgian- and Swiss-based investors, Serina is best viewed as an early-stage biotech whose equity story is primarily driven by clinical milestones, regulatory execution, and financing events rather than by recurring commercial revenue. The company was founded in 2006 and is headquartered in Huntsville, Alabama, United States. Its core strategy is built around a proprietary drug-optimization engine, the POZ Platform™, designed to improve the pharmacokinetic profile, tolerability, and delivery characteristics of known therapies and other modalities. Serina’s business is centered on developing product candidates for neurological diseases and potentially other indications. Its lead asset is SER-252, a POZylated version of apomorphine being advanced for advanced Parkinson’s disease. The company is positioning SER-252 as a differentiated therapy intended to provide more stable exposure to the active ingredient, with subcutaneous weekly or twice-weekly dosing designed to improve symptom control and patient convenience. Beyond Parkinson’s disease, Serina describes the POZ Platform as potentially applicable to small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs), which gives the company a broader platform narrative than a single-asset biotech. From a competitive standpoint, Serina is not a commercial pharmaceutical company competing on sales scale; it is a specialty biotech competing on technology differentiation, intellectual property, and clinical proof-of-concept. The investment case is therefore asymmetric: if the platform can meaningfully improve established molecules, it could create value across multiple programs, but if the lead clinical program disappoints, downside risk is substantial. The company’s current market position reflects that profile: pre-commercial, platform-driven, and highly dependent on development execution. Recent news flow has been material. In January 2026, the FDA cleared the Investigational New Drug application for SER-252. In February 2026, Serina announced first patient enrollment in its Phase 1b registrational study in advanced Parkinson’s disease. In March and April 2026, the company closed a private placement that could provide up to $30 million in gross proceeds, strengthening the balance sheet for ongoing development. In its first-quarter 2026 update, Serina said the Phase 1b study is underway and that cohort enrollment remains on track, while it also highlighted continued financing activity and clinical progress. The company also reported that NYSE American accepted its continued-listing compliance plan. Overall, Serina remains a small-cap clinical biotech whose valuation is likely to be dominated by SER-252 data, regulatory progress, and capital-market access over the next several quarters.